Corrections to “Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up”

Le résumé fourni par la source

Ann Oncol 2018; 29: iv51–iv67 (doi:10.1093/annonc/mdy096) The following corrections have been made under authorship: The author R.L. Haas has been added with the corresponding affiliation and author disclosure statement. The author name P. Rutkovski has been replaced with: P. Rutkowski Under authorship, the author name: A. Hannu has been replaced with: H.T. Aro. Under authorship, A. A. Safwat s affiliation: Finland has been replaced with: Denmark. Under authorship, the author name: W. Van der Graaf has been replaced with: W.T.A. van der Graaf. W.T.A. van der Graaf s institution: 30 has been replaced with: 30, 33, 51. In “Figure 4. 4. Management of advanced, clinically unresectable STS” Doxorubicin Doxorubicin + ifosfamide Doxorubicin + olaratumab [I, A] Has been replaced with: Doxorubicin [I, A] Doxorubicin + ifosfamide [I, B] Doxorubicin + olaratumab [II, C] Under the section “References” A reference has been updated: 2. Blay JY, Bertuzzi A, Bielack S et al. Bone sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2014; 25(Suppl 3): iii113–iii123. has been replaced with: 2. PG Casali, S. Bielack, N. Abecassis et al. Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018: 29(Suppl 4): iv79–iv95. Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of OncologyVol. 29PreviewSoft tissue sarcomas (STSs) gather over 80 histological entities, with even more molecular subsets, characterised by a low to very low incidence in all populations. The majority of sarcomas arise from the soft tissue (close to 75%), with ∼15% gastrointestinal stromal tumours (GISTs) and 10% bone sarcomas. These ESMO–EURACAN (European Society for Medical Oncology–European Reference Network for rare adult solid cancers) Clinical Practice Guidelines cover STSs, while GISTs are covered by dedicated ESMO–EURACAN Clinical Practice Guidelines [1]. Full-Text PDF Open Archive

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.